[Preparation of dihydrocarminomycin and a comparison of its antitumor activity with the activity of carminomycin].
A dihydro derivative of karminomycin was prepared using chemical reduction with potassium boron hydride. When dihydrokarminomycin was administered intravenously to healthy albino mice in a single dose it practically showed the same toxicity as karminomycin. However, unlike the latter dihydrokarminomycin induced the death of the animals at later periods of time. Studies on mice with transplantable tumours showed high antitumor activity of dihydrokarminomycin against lymphosarcoma L10-1, sarcoma 180, Garding-Passy melanoma, lymphoid leukosis L-1210 and lymphocytal leukosis P-388. In treatment of the mice with leukosis L-1210 and Garding-Passy melanoma dihydrokapminomycin was much inferior by its efficiency than karminomycin.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002360:Carubicin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use*; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D012510:Sarcoma 180 / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D002360:Carubicin
Poluchenie digidrokarminomitsina i sravnenie ego protivoopukholevoĭ aktivnosti s aktivnost'iu karminomitsina